It was conducted across a nation-wide network of 23 hospitals, recruiting over 230 participants to take part. The courageous participants were randomly assigned at the start of the trial to take either simvastatin or a placebo treatment for 2 years and undergo regular clinical assessments.
The results of that study have been released and they indicate that the treatment has had no impact on slowing the progression of Parkinson’s. The results of the study were presented by Dr Carroll at the virtual 2020 Movement Disorder Society meeting.
“Given the strength of pre-clinical evidence, and the progress with simvastatin already being made in MS, this is a disappointing result. However, we now have a definitive answer, and that enables us to move forward to test a number of other drugs of interest, many of which have been used to treat other diseases, and all of which we have determined have compelling evidence they each have the potential to modify Parkinson’s progression.”
Dr Richard Wyse, Director of Research & Development at The Cure Parkinson’s Trust
We are sorry that this content was not useful for you
Let us improve this content
Can you tell us how we can improve this content?